The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-warns-secondary-blood-cancer-risk-tazverik-2026a1000fil?src=rss
Author :
Publish date : 2026-05-13 18:02:00
Copyright for syndicated content belongs to the linked Source.